The move comes after a product alert was issued by the U.S. Food and Drug Administration warning that the products contain low levels of nitrosodimethylamine (NDMA).
Zantac has not currently been recalled, but the FDA is researching to determine if the low levels of NDMA pose a risk. The initial report found that the amounts “barely exceed amounts found in common foods.”
CVS was first to pull the product, announcing the move Saturday, Sept. 28.
“This action is being taken out of an abundance of caution due to a recent Product Alert from the U.S. Food and Drug Administration that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen,” CVS said in a statement.
Walgreens said in a statement on Monday, Sept. 30 that the company had pulled the drug from its shelves “while the FDA continues its review of the products.”
Rite Aid said it was “in the process of removing Zantac and generic versions sold under the Rite Aid name from its shelves.”
Click here to follow Daily Voice Shelton and receive free news updates.